The outcomes highlight distinctive metabolic changes linked to specific APOE genotypes in DN development, indicating varying impacts on lipid profiles, glucose metabolism, and insulin sensitivity. Indeed, the DN subjects have markedly altered biochemical and clinical profiles compared to Controls, with significant differences observed in lipid profiles, glucose metabolism, and renal function markers. The gene discussed is APOE; the disease is liver dysplastic nodule.